Table of Contents Table of Contents
PowerPoint-presentatie Next Page
Information
Show Menu
PowerPoint-presentatie Next Page

 


day 2 		1
L1.1 MR - Tx Delivery technologies v3.pdf 		1
Slide Number 1 		1
Slide Number 2 		2
Treatment Delivery Technologies in BrachytherapyProf. Mark J. Rivard, Ph.D., FAAPM 		3
Disclosures 		4
Learning Objectives 		5
Slide Number 6 		6
Slide Number 7 		7
Slide Number 8 		8
Slide Number 9 		9
Slide Number 10 		10
Slide Number 11 		11
Slide Number 12 		12
Slide Number 13 		13
Slide Number 14 		14
Slide Number 15 		15
Slide Number 16 		16
Slide Number 17 		17
Slide Number 18 		18
Slide Number 19 		19
Slide Number 20 		20
Slide Number 21 		21
Slide Number 22 		22
Slide Number 23 		23
Slide Number 24 		24
Slide Number 25 		25
Slide Number 26 		26
Slide Number 27 		27
Slide Number 28 		28
Slide Number 29 		29
Slide Number 30 		30
Slide Number 31 		31
Slide Number 32 		32
Slide Number 33 		33
Slide Number 34 		34
Slide Number 35 		35
Slide Number 36 		36
Slide Number 37 		37
Slide Number 38 		38
Slide Number 39 		39
Slide Number 40 		40
Slide Number 41 		41
Slide Number 42 		42
Slide Number 43 		43
Slide Number 44 		44
Slide Number 45 		45
Slide Number 46 		46
Slide Number 47 		47
Slide Number 48 		48
Slide Number 49 		49
L1.2 DB - The Principles of Treatment Planning 		50
Slide Number 1 		50
Slide Number 2 		51
Slide Number 3 		52
Slide Number 4 		53
Slide Number 5 		54
Slide Number 6 		55
Slide Number 7 		56
Slide Number 8 		57
Slide Number 9 		58
Slide Number 10 		59
Slide Number 11 		60
Slide Number 12 		61
Slide Number 13 		62
Slide Number 14 		63
Slide Number 15 		64
Slide Number 16 		65
Slide Number 17 		66
Slide Number 18 		67
Slide Number 19 		68
Slide Number 20 		69
Slide Number 21 		70
Slide Number 22 		71
Slide Number 23 		72
Slide Number 24 		73
Slide Number 25 		74
Slide Number 26 		75
Slide Number 27 		76
Slide Number 28 		77
Slide Number 29 		78
Slide Number 30 		79
Slide Number 31 		80
Slide Number 32 		81
Slide Number 33 		82
Slide Number 34 		83
Slide Number 35 		84
Slide Number 36 		85
Slide Number 37 		86
Slide Number 38 		87
Slide Number 39 		88
Slide Number 40 		89
Slide Number 41 		90
Slide Number 42 		91
Slide Number 43 		92
Slide Number 51 		93
Slide Number 52 		94
Slide Number 53 		95
Slide Number 54 		96
Slide Number 55 		97
Slide Number 56 		98
Slide Number 57 		99
Slide Number 58 		100
Slide Number 59 		101
Slide Number 60 		102
Slide Number 61 		103
Slide Number 62 		104
Slide Number 63 		105
L1.3 CK 3D imaging_2016 		106
L1.4 LB - Tissue Segmentation and Characterization_LB 		194
L1.5 LB - QA of 3D imaging 		243
L1.6 MR - 3D imaging reconstructions v2 		286
Slide Number 1 		286
Slide Number 2 		287
Catheter/Applicator and Source Localisationusing 3D ImagingProf. Mark J. Rivard, Ph.D., FAAPM 		288
Disclosures 		289
Learning Objectives 		290
Slide Number 6 		291
Slide Number 7 		292
Slide Number 8 		293
Slide Number 9 		294
Slide Number 10 		295
Slide Number 11 		296
Slide Number 12 		297
Slide Number 13 		298
Slide Number 14 		299
Slide Number 15 		300
Slide Number 16 		301
Slide Number 17 		302
Slide Number 18 		303
Slide Number 19 		304
Slide Number 20 		305
Slide Number 21 		306
Slide Number 22 		307
Slide Number 23 		308
Test Assumptions: Reconstruction Commissioning 		309
Slide Number 25 		310
Slide Number 26 		311
Slide Number 27 		312
Slide Number 28 		313
Slide Number 29 		314
Slide Number 30 		315
Slide Number 31 		316
Slide Number 32 		317
Slide Number 33 		318
Slide Number 34 		319
Slide Number 35 		320
Slide Number 36 		321
Slide Number 37 		322
Test Assumptions: Reconstruction Commissioning 		323
Slide Number 39 		324
Slide Number 40 		325
Slide Number 41 		326
Batchelar, et al. Brachytherapy 2014;13:75-9.De BraBandere, et al. Brachytherapy 2013;12:580-8.Hellebust, et al. Radiother Oncol 2010;96:153-60.Holupka, et al. Med Phys 2004;31:2672-9.Jain, et al. Med Phys 2005;32:3475-92.Kim, et al. Med Phys 2004;31:2543-8.Lam, et al. Phys Med Biol 2004;49:557-69.Li, et al. Med Phys 2001;28:1410-5.Liu, et al. Phys Med Biol 2003;48:1191-203.Milickovic, et al. Med Phys 2000;27:1047-57.Milickovic, et al. Phys Med Biol 2000;45:2787-800.Narayanan, et al. Med Phys 2002;29:1572-9.Narayanan, et al. Phys Med Biol 2004;49:3483-94.Roué, et al. Radiother Oncol 2006;78:78-83.Schindel, et al. J Contemp Brachy 2013;5:250-7.Siebert, et al. Med Phys 2009;36:3406-12.Todor, et al. Phys Med Biol 2002;47:2031-48.Venselaar and Perez-Calatayud, 2004. ESTRO Booklet 8. 		327
Slide Number 43 		328
Slide Number 44 		329
ABP Vienna 2016 - Day 2 		330
Slide Number 1 		369
Slide Number 2 		370
Background and Details on TG-43 Based DosimetryProf. Mark J. Rivard, Ph.D., FAAPM 		371
Disclosures 		372
Learning Objectives 		373
Slide Number 6 		374
Slide Number 7 		375
Slide Number 8 		376
Slide Number 9 		377
Slide Number 10 		378
Slide Number 11 		379
Slide Number 12 		380
Slide Number 13 		381
Slide Number 14 		382
Slide Number 15 		383
Slide Number 16 		384
Slide Number 17 		385
Slide Number 18 		386
Slide Number 19 		387
Slide Number 20 		388
Slide Number 21 		389
Slide Number 22 		390
Slide Number 23 		391
Slide Number 24 		392
Slide Number 25 		393
Slide Number 26 		394
Slide Number 27 		395
Slide Number 28 		396
Slide Number 29 		397
Slide Number 30 		398
Slide Number 31 		399
Slide Number 32 		400
Slide Number 33 		401
Slide Number 34 		402
Slide Number 35 		403
Slide Number 36 		404
Slide Number 37 		405
Slide Number 38 		406
Slide Number 39 		407
Slide Number 40 		408
Ballester, et al. Med Phys 2009;36:4250-6.Beaulieu, et al. Med Phys 2012;39:6208-36.Butler, et al. Med Phys 2008;35:3860-5.DeWerd, et al. Med Phys 2011;38:782-801.Granero, et al. Med Phys 2011;38:487-94.Kirisits, et al. Radiat Oncol 2014;110:199-212.Nath, et al. Med Phys 1995;22:209-34.Perez-Calatayud, et al. Med Phys 2012;39:2904-29. Rivard, Med Phys 1999;26:2445-50. Rivard, Appl Radiat Isot 2001;55:755-82. Rivard, et al. Med Phys 2004;31:633-74. Rivard, et al. Nuc Sci Engin 2005;149:101-6. Rivard, et al. Med Phys 2007;34:2187-205.Rivard, et al. Med Phys 2009;36:1968-75.Rivard, et al. Med Phys 2009;36:2136-53.Thomadesn, et al. Med Phys 2008;35:4708-23. 		409
day 3 		640
L3.1 CK - evaluation_2016.pdf 		640
L3.2 CK - prescribing_2016 		701
L3.3 DB - Optimization and Inverse Planning 		759
Slide Number 1 		759
Slide Number 2 		760
Slide Number 3 		761
Slide Number 4 		762
Slide Number 5 		763
Slide Number 6 		764
Slide Number 7 		765
Slide Number 8 		766
Slide Number 9 		767
Slide Number 10 		768
Slide Number 11 		769
Slide Number 12 		770
Slide Number 13 		771
Slide Number 14 		772
Slide Number 15 		773
Slide Number 16 		774
Slide Number 17 		775
Slide Number 18 		776
Slide Number 19 		777
Slide Number 20 		778
Slide Number 21 		779
Slide Number 22 		780
Slide Number 23 		781
Slide Number 24 		782
Slide Number 25 		783
Slide Number 26 		784
Slide Number 27 		785
Slide Number 28 		786
Slide Number 29 		787
Slide Number 30 		788
Slide Number 31 		789
Slide Number 32 		790
Slide Number 33 		791
Slide Number 34 		792
Slide Number 35 		793
Slide Number 36 		794
Slide Number 37 		795
Slide Number 38 		796
Slide Number 39 		797
Slide Number 40 		798
Slide Number 41 		799
Slide Number 42 		800
Slide Number 43 		801
The penalisation of the individual objective functions: 		802
Slide Number 45 		803
Slide Number 46 		804
Slide Number 47 		805
Slide Number 48 		806
Slide Number 49 		807
Slide Number 50 		808
Slide Number 51 		809
Slide Number 52 		810
Slide Number 53 		811
Slide Number 54 		812
Slide Number 55 		813
Slide Number 56 		814
Slide Number 57 		815
Slide Number 58 		816
Slide Number 59 		817
Slide Number 60 		818
Slide Number 61 		819
Slide Number 63 		820
Slide Number 64 		821
Slide Number 65 		822
Slide Number 66 		823
Slide Number 67 		824
L3.4 MR - source strength determinations v2 		825
L3.5 PP - Experimental Dos 		884
L3.6 DB - Treatment Delivery Verification 		944
L3.7 LB - In Vivo Dosimetry 		985
day 4 		1054
L4.1 NN - uncertainties_2016.pdf 		1054
L4.2 MR - QMP Elements v3 		1105
L4.3 LB - FutureI-Tracking Tech V2 		1168
L4.4 MR - Future v2 		1212
 FlippingBook